Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.

BACKGROUND Distant metastases (DM) are a rare occurrence in well-differentiated thyroid carcinoma. The aim of this study was to analyze the clinical, pathologic, and molecular features of primary thyroid carcinoma with low-risk histology that develop DM. METHODS A detailed clinicopathologic review and targeted next-generation sequencing were performed on a cohort of well-differentiated thyroid carcinoma lacking gross extrathyroidal extension, extensive vascular invasion, or significant lymph node metastases but exhibiting DM. RESULTS Primary well-differentiated thyroid carcinoma with low-risk histologic features and DM was a rare occurrence, accounting for only 3% of metastatic non-anaplastic thyroid carcinoma. All 15 cases meeting the inclusion criteria harbored DM at presentation. The majority (11/15) of these tumors were follicular variant of papillary thyroid carcinoma (PTC), especially the encapsulated form (n = 8). The remaining patients harbored encapsulated Hürthle cell carcinoma (n = 2), encapsulated follicular carcinoma (n = 1), and an encapsulated papillary carcinoma classical variant (n = 1). Of the 12 encapsulated carcinomas, 10 had capsular invasion only and no vascular invasion. Ninety-two percent of the tumors exhibited extensive intra-tumoral fibrosis. Among the eight tumors that were subjected to next-generation sequencing analysis, a RAS mutation was the main driver (5/8), and TERT promoter mutation was highly prevalent (6/8). In four cases, TERT promoter mutations were associated with RAS or BRAF mutations. BRAF-mutated classical variant of papillary carcinoma also presented with DM but was less common (1/8). In 11/15 cases, the clinician was able to diagnose distant disease based on the clinical presentation. In 3/4 incidental cases that were genotyped, TERT promoter mutations were found. CONCLUSIONS When DM occur in primary thyroid carcinoma with low-risk histology, they are almost always found at presentation. The majority are encapsulated follicular variant of PTC with capsular invasion only. TERT promoter mutations occur at a higher rate than that seen in PTC in general and may help explain the aggressive behavior of these histologically deceptive primary carcinomas.

[1]  Y. Min,et al.  Prognostic Implications of Radioiodine Avidity and Serum Thyroglobulin in Differentiated Thyroid Carcinoma with Distant Metastasis , 2013, World Journal of Surgery.

[2]  E. Bergstralh,et al.  Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. , 1992, Surgery.

[3]  S. Piana,et al.  Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases: report of 3 cases, with morphological and molecular analysis. , 2013, Human pathology.

[4]  Bin Xu,et al.  Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma , 2016, Endocrine Pathology.

[5]  J. Shah,et al.  Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis , 2006, Cancer.

[6]  R. Tsang,et al.  Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis , 2007, Cancer.

[7]  T. Uruno,et al.  Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. , 2011, Thyroid : official journal of the American Thyroid Association.

[8]  J. Mihailovič,et al.  Metastatic differentiated thyroid carcinoma: clinical management and outcome of disease in patients with initial and late distant metastases , 2009, Nuclear medicine communications.

[9]  E. Bergstralh,et al.  Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. , 1988, The Journal of clinical endocrinology and metabolism.

[10]  David D. Smith,et al.  The Implication of Lymph Node Metastasis on Survival in Patients with Well-Differentiated Thyroid Cancer , 2005, The American surgeon.

[11]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[12]  L. Pomorski,et al.  Metastasis as the first sign of thyroid cancer. , 1999, Neoplasma.

[13]  J. Mihailovič,et al.  Differentiated thyroid carcinoma with distant metastases: probability of survival and its predicting factors. , 2007, Cancer biotherapy & radiopharmaceuticals.

[14]  R. Celestino,et al.  TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas , 2014, The Journal of clinical endocrinology and metabolism.

[15]  C. Hsieh,et al.  Long‐term outcomes of distant metastasis from differentiated thyroid carcinoma , 2012, Clinical endocrinology.

[16]  J. Ricarte-Filho,et al.  Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns , 2010, Modern Pathology.

[17]  Jandee Lee,et al.  Differentiated Thyroid Carcinoma Presenting With Distant Metastasis at Initial Diagnosis: Clinical Outcomes and Prognostic Factors , 2010, Annals of surgery.

[18]  D. Yin,et al.  Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta‐analysis , 2016, Clinical endocrinology.

[19]  B. Lang,et al.  Evaluating the Prognostic Factors Associated with Cancer-specific Survival of Differentiated Thyroid Carcinoma Presenting with Distant Metastasis , 2012, Annals of Surgical Oncology.

[20]  M. Monden,et al.  Fatal differentiated thyroid cancer , 1996, Journal of surgical oncology.

[21]  C. Sander,et al.  Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. , 2016, The Journal of clinical investigation.

[22]  Simion I. Chiosea,et al.  Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules. , 2016, Endocrine-related cancer.

[23]  S. Mane,et al.  Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. , 2015, Human molecular genetics.

[24]  R. Ghossein Encapsulated Malignant Follicular Cell-Derived Thyroid Tumors , 2010, Endocrine pathology.

[25]  J. Shah,et al.  Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. , 1996, American journal of surgery.

[26]  R. DeLellis Pathology and genetics of tumours of endocrine organs , 2004 .

[27]  O. Ozaki,et al.  Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. , 1999, The Journal of clinical endocrinology and metabolism.

[28]  I. Okayasu,et al.  Papillary thyroid carcinoma with heterotopic ossification is a special subtype with extensive progression. , 2013, American journal of clinical pathology.

[29]  I. Ganly,et al.  Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas. , 2016, Thyroid : official journal of the American Thyroid Association.